Investigational drug · Phase 3
ALXN1850
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypophosphatasia.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "ALXN1850"
First trial start
2024
Jan 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALXN1850", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypophosphatasia
Largest trials
Live from ClinicalTrials.gov: studies naming "ALXN1850" as an intervention, largest first.
- Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase AlfaPivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06079281 · 124 participants · Start Jan 3, 2024 · Primary completion Jul 9, 2025
Drug: ALXN1850; Placebo · For: Hypophosphatasia
Sites: Indianapolis, Indiana; Garden City, New York; Durham, North Carolina · 65 sites in all
- Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase AlfaPivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06079372 · 43 participants · Start Apr 2, 2024 · Primary completion Jul 23, 2025
Drug: ALXN1850; asfotase alfa · For: Hypophosphatasia
Sites: Hartford, Connecticut; Baltimore, Maryland; Minneapolis, Minnesota · 21 sites in all
- Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPPPivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06079359 · 30 participants · Start May 14, 2024 · Primary completion Jan 6, 2026
Drug: ALXN1850; Placebo · For: Hypophosphatasia
Sites: Baltimore, Maryland; Kansas City, Missouri; Durham, North Carolina · 32 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04980248 · 15 participants · Start Sep 28, 2021 · Primary completion Aug 24, 2022
Drug: ALXN1850 · For: Hypophosphatasia
Sites: Las Vegas, Nevada; Columbus, Ohio; Nashville, Tennessee · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia.
Dahir KM, Shannon A, Dunn D, et al. · J Bone Miner Res 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.